We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




NGS Blood Test Qualitatively Detects Thalassemia Mutations

By LabMedica International staff writers
Posted on 05 Sep 2022
Print article
Image: Preventing and treating thalassemia with genomics (Photo courtesy of BGI Genomics)
Image: Preventing and treating thalassemia with genomics (Photo courtesy of BGI Genomics)

Thalassemia is an inherited blood disorder caused by an abnormal hemoglobin molecule, which inhibits the body’s ability to produce hemoglobin or red blood cells. Thalassemia occurs in approximately 4.4 out of every 10,000 live births throughout the world. The impact ranges from mild to severe, and can be life-threatening. It has been estimated that 5-7% of the world's population carries a mutated gene affecting the production or function of the hemoglobin molecule. Genomics has helped doctors better understand the abnormal hemoglobin molecule causing thalassemia and other hemoglobinopathies, thereby enabling more targeted treatments for patients. Now, a detection kit based on the combinatorial probe-anchor synthesis sequencing method, a next-generation sequencing (NGS) technology, can qualitatively detect α-thalassemia and β thalassemia mutations.

BGI Genomics’ (Shenzhen, China) Thalassemia Gene Detection Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method) has recently obtained CE-IVDD approval, expanding the availability of genetic testing in the screening, diagnosis and treatment of thalassemia. Peripheral blood samples can be used for genetic screening of the general population for α and/or β thalassemia mutations, and diagnosis of patients and suspected patients with these mutations as well as abnormal hemoglobinopathy. In high-prevalence regions of the world, hemoglobin disorders such as thalassemia, constitute a serious medical and public health problem. These regions include the Mediterranean, the Middle Eastern and North African (MENA) region, Central Asia, the Indian subcontinent, and Southeast Asia.

"Screening for thalassemia through genetic testing is vital so that carriers and at-risk couples may be informed about their risk and the options for reducing it," said Jingjing Xiao, BGI Genomics Senior Product Manager. "These genetic tests are also the gold standard for the diagnosis of thalassemia."

Related Links:
BGI Genomics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.